LT3133080T - Naujieji citostatiniai 7-deazapurino nukleozidai - Google Patents

Naujieji citostatiniai 7-deazapurino nukleozidai

Info

Publication number
LT3133080T
LT3133080T LTEP16174985.8T LT16174985T LT3133080T LT 3133080 T LT3133080 T LT 3133080T LT 16174985 T LT16174985 T LT 16174985T LT 3133080 T LT3133080 T LT 3133080T
Authority
LT
Lithuania
Prior art keywords
deazapurine nucleosides
novel cytostatic
cytostatic
novel
deazapurine
Prior art date
Application number
LTEP16174985.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of LT3133080T publication Critical patent/LT3133080T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LTEP16174985.8T 2008-01-18 2009-01-15 Naujieji citostatiniai 7-deazapurino nukleozidai LT3133080T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
LT3133080T true LT3133080T (lt) 2018-11-12

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP16174985.8T LT3133080T (lt) 2008-01-18 2009-01-15 Naujieji citostatiniai 7-deazapurino nukleozidai
LTEP09702842.7T LT2231689T (lt) 2008-01-18 2009-01-15 Nauji citostatiniai 7-deazapurino nukleozidai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP09702842.7T LT2231689T (lt) 2008-01-18 2009-01-15 Nauji citostatiniai 7-deazapurino nukleozidai

Country Status (18)

Country Link
US (1) US8093226B2 (enExample)
EP (2) EP3133080B1 (enExample)
JP (2) JP5485172B2 (enExample)
CN (1) CN101977923B (enExample)
AU (1) AU2009204568B2 (enExample)
CA (1) CA2711384C (enExample)
CY (2) CY1118104T1 (enExample)
DK (2) DK2231689T3 (enExample)
ES (2) ES2693551T3 (enExample)
HR (2) HRP20161344T1 (enExample)
HU (2) HUE041598T2 (enExample)
LT (2) LT3133080T (enExample)
NZ (1) NZ586610A (enExample)
PL (2) PL3133080T3 (enExample)
PT (2) PT3133080T (enExample)
SI (2) SI3133080T1 (enExample)
TR (1) TR201815961T4 (enExample)
WO (1) WO2009089804A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US9321800B2 (en) * 2009-04-22 2016-04-26 Gilead Sciences, Inc. 7-deazapurine nucleosides for therapeutic uses
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
NZ596479A (en) * 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR102242077B1 (ko) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2018001393A1 (en) 2016-06-29 2018-01-04 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
KR20260080448A (ko) 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
US20220267365A1 (en) * 2019-06-18 2022-08-25 Taiho Pharmaceutical Co., Ltd. Novel phosphate ester compound having pyrrolopyrimidine skeleton or pharmaceutically acceptable salt thereof
EP4106763A1 (en) * 2020-02-17 2022-12-28 Katholieke Universiteit Leuven KU Leuven Research & Development Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (enExample) * 1974-03-19 1975-10-01
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
WO2005021568A2 (en) * 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
PL2231689T3 (pl) 2017-01-31
CA2711384A1 (en) 2009-07-23
AU2009204568B2 (en) 2013-10-03
PT2231689T (pt) 2016-10-07
DK2231689T3 (en) 2016-09-19
EP3133080B1 (en) 2018-08-01
AU2009204568A1 (en) 2009-07-23
HUE041598T2 (hu) 2019-05-28
NZ586610A (en) 2012-08-31
JP2011509949A (ja) 2011-03-31
US20090203637A1 (en) 2009-08-13
CN101977923B (zh) 2014-10-08
LT2231689T (lt) 2016-10-25
US8093226B2 (en) 2012-01-10
ES2598503T3 (es) 2017-01-27
JP2014058567A (ja) 2014-04-03
TR201815961T4 (tr) 2018-11-21
CN101977923A (zh) 2011-02-16
SI2231689T1 (sl) 2016-11-30
HUE030767T2 (en) 2017-05-29
PL3133080T3 (pl) 2018-12-31
CY1118104T1 (el) 2017-06-28
CY1121364T1 (el) 2020-05-29
CA2711384C (en) 2016-07-26
EP2231689A1 (en) 2010-09-29
HRP20161344T1 (hr) 2016-11-18
EP3133080A1 (en) 2017-02-22
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
EP2231689B1 (en) 2016-07-20
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
JP5485172B2 (ja) 2014-05-07
SI3133080T1 (sl) 2018-12-31
ES2693551T3 (es) 2018-12-12

Similar Documents

Publication Publication Date Title
SI2231689T1 (sl) Novi citostatski 7-deazapurinski nukleozidi
IL210855A0 (en) Novel adenine derivatives
ZA201008829B (en) Nucleoside cyclicphosphates
PL2421879T3 (pl) Nowe nukleozydy 7-deazapurynowe do zastosowań terapeutycznych
IL213698A0 (en) Nucleoside phosphoramidates
IL213700A0 (en) Nucleoside analogs
IL200831A0 (en) Novel adenine compounds
IL205625A0 (en) Antiviral nucleoside compounds
IL213701A0 (en) Synthesis of purine nucleosides
IL202623A0 (en) Antiviral compounds
IL210207A0 (en) Compounds having antiviral properties
IL213167A0 (en) Purine compounds
IL208351A0 (en) Antiviral therapy
GB0818472D0 (en) Composition
GB0803707D0 (en) Antiviral agent
GB0723609D0 (en) Antiviral
HK1149016A (en) Novel cytostatic 7-deazapurine nucleosides
ZA201005416B (en) Cytostatic composition
GB0819528D0 (en) Antiviral compounds
IL192335A0 (en) Antiviral compounds
GB0816600D0 (en) Antiviral compounds
GB0704852D0 (en) Furanose derivatives
GB0717955D0 (en) Preparation of modified nucleosides
GB0803654D0 (en) Buster brackets (KA-2 + KA-9)
GB0819857D0 (en) Antiviral therapy